Risk of Diabetes Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2010 Jun 30

PMID 20584807

Citations 84

Authors

Daniel H Solomon

Thorvardur Jon Love

Claire Canning

Sebastian Schneeweiss

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the risk of diabetes mellitus (DM) among subjects with rheumatoid arthritis (RA), psoriatic arthritis or psoriasis (PsA/PsO), compared with non-rheumatic controls.

Methods: Study cohorts were assembled using linked healthcare utilisation data from British Columbia. All people with at least two diagnoses of RA or PsA/PsO were included and compared with a cohort of people without any known rheumatic disease. The outcome of interest was a diagnosis of new-onset DM, as defined by initiation of an antidiabetic drug. Incidence rates (IRs) per 1000 person-years and IR ratios were calculated and Cox regression models were constructed to determine the hazard ratio (HR) for diabetes by age, gender, systemic immunosuppressive drug and glucocorticoid use.

Results: The study cohort comprised 48 718 subjects with RA, 40 346 with PsA/PsO and 442 033 without any rheumatic disease. The IR for DM among subjects with RA was 8.6 per 1000 person-years (95% CI 8.5 to 8.7), PsA/PsO 8.2 (95% CI 8.1 to 8.3) and for non-rheumatic controls 5.8 (95% CI 5.8 to 5.8). The adjusted HR for RA compared with non-rheumatic controls was 1.5 (95% CI 1.4 to 1.5) and 1.4 (95% CI 1.3 to 1.5) for PsA/PsO.

Conclusions: RA and PsA/PsO appear to be associated with an increased risk of DM. The ability of potent antirheumatic treatments to reverse this trend warrants study.

Citing Articles

Prevalence of comorbidities among patients with rheumatoid arthritis in the UAE: a case-control study.

Al-Saleh J, Ali Khan N, Zamani N, AlSaidi H, Rachidi W BMJ Open. 2024; 14(11):e086116.

PMID: 39532347 PMC: 11574516. DOI: 10.1136/bmjopen-2024-086116.

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.

McCormick N, Yokose C, Lu N, Wexler D, Avina-Zubieta J, De Vera M BMJ. 2024; 387():e080035.

PMID: 39477370 PMC: 11524131. DOI: 10.1136/bmj-2024-080035.

Increased risk of adverse events among patients with vs. without systemic autoimmune rheumatic disease prescribed sodium-glucose cotransporter 2 inhibitors: a retrospective cohort study.

Oakes E, Ellrodt J, Guan H, Yee J, Choi M, Costenbader K Clin Rheumatol. 2024; 43(12):3839-3847.

PMID: 39448504 DOI: 10.1007/s10067-024-07206-w.

Identification of common genetic factors and immune-related pathways associating more than two autoimmune disorders: implications on risk, diagnosis, and treatment.

Rajalingam A, Ganjiwale A Genomics Inform. 2024; 22(1):10.

PMID: 38956704 PMC: 11221123. DOI: 10.1186/s44342-024-00004-5.

Risk for cardiovascular disease development in rheumatoid arthritis.

Bedekovic D, Bosnjak I, Bilic-Curcic I, Kirner D, Saric S, Novak S BMC Cardiovasc Disord. 2024; 24(1):291.

PMID: 38834973 PMC: 11149346. DOI: 10.1186/s12872-024-03963-3.

References

Solomon D, Karlson E, Rimm E, Cannuscio C, Mandl L, Manson J . Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107(9):1303-7. DOI: 10.1161/01.cir.0000054612.26458.b2. View

Qureshi A, Choi H, Setty A, Curhan G . Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009; 145(4):379-82. PMC: 2849106. DOI: 10.1001/archdermatol.2009.48. View

Solomon D, Goodson N, Katz J, Weinblatt M, Avorn J, Setoguchi S . Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006; 65(12):1608-12. PMC: 1798453. DOI: 10.1136/ard.2005.050377. View

Wilchesky M, Tamblyn R, Huang A . Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004; 57(2):131-41. DOI: 10.1016/S0895-4356(03)00246-4. View

Neimann A, Shin D, Wang X, Margolis D, Troxel A, Gelfand J . Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55(5):829-35. DOI: 10.1016/j.jaad.2006.08.040. View

Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs J . Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004; 53(7):1782-9. DOI: 10.2337/diabetes.53.7.1782. View

Maradit-Kremers H, Nicola P, Crowson C, Ballman K, Gabriel S . Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005; 52(3):722-32. DOI: 10.1002/art.20878. View

Tam L, Tomlinson B, Chu T, Li T, Li E . Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007; 26(9):1495-8. DOI: 10.1007/s10067-007-0539-8. View

Gonzalez-Gay M, de Matias J, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J . Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24(1):83-6. View

10.

Chen Y, Wu C, Shen J, Chu S, Chen C, Chang Y . Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008; 144(12):1571-5. DOI: 10.1001/archderm.144.12.1571. View

11.

Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L . Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006; 55(4):1133-40. DOI: 10.2337/diabetes.55.04.06.db05-1076. View

12.

Klover P, Zimmers T, Koniaris L, Mooney R . Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003; 52(11):2784-9. DOI: 10.2337/diabetes.52.11.2784. View

13.

Rothman K, Poole C . A strengthening programme for weak associations. Int J Epidemiol. 1988; 17(4):955-9. DOI: 10.1093/ije/17.4.955. View

14.

Rotter V, Nagaev I, Smith U . Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278(46):45777-84. DOI: 10.1074/jbc.M301977200. View

15.

Brauchli Y, Jick S, Meier C . Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol. 2008; 159(6):1331-7. DOI: 10.1111/j.1365-2133.2008.08814.x. View

16.

Romano P, Roos L, Jollis J . Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46(10):1075-9; discussion 1081-90. DOI: 10.1016/0895-4356(93)90103-8. View

17.

Yang X, Tisch R, Singer S, Cao Z, Liblau R, Schreiber R . Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 1994; 180(3):995-1004. PMC: 2191653. DOI: 10.1084/jem.180.3.995. View

18.

Wasko M, Hubert H, Lingala V, Elliott J, Luggen M, Fries J . Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007; 298(2):187-93. DOI: 10.1001/jama.298.2.187. View

19.

del Rincon I, Williams K, Stern M, Freeman G, Escalante A . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2002; 44(12):2737-45. DOI: 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-%23. View

20.

Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A . Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14):1735-41. DOI: 10.1001/jama.296.14.1735. View